Publications from Johnson & Johnson, page 31
A filtered view. Show the full list.
Refine
Listings
-
ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Real-World Assessment of All-Cause Hospital Readmissions among Pulmonary Embolism Patients Treated With Rivaroxaban Versus Apixaban
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Venous Thromboembolism Patients with Comorbid Obstructive Sleep Apnea: A Retrospective Cohort Study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportAntiviral therapy
Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleTherapeutic advances in musculoskeletal disease
Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleBlood
Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Disease researchAdded
-
Clinical trial reportBlood
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportBlood
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleBlood
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Disease researchAdded
-
Clinical trial reportBlood
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Disease researchAdded
-
ArticleBlood advances
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportBlood advances
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleBlood advances
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Disease researchAdded
-
ArticleBMC infectious diseases
A qualitative burden of disease study in patients with invasive Escherichia coli disease aged ≥ 60 years in the United States
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Disease researchAdded
-
ArticleBMC psychiatry
Clinical burden of major depressive disorder with versus without prominent anhedonia using a real-world electronic health records and claims linked database
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Disease researchAdded
-
ArticleBMC health services research
Economic outcomes of diabetes self-management education among older Medicare beneficiaries with diabetes
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleTrials
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial
Verified Author affiliations on the Europe PMC record name Drexel University College of Medicine, Johnson & Johnson, Perelman School of Medicine, with Drexel University, University of Pennsylvania linked by the institution reference. Affiliation source
Clinical careAdded
-
ArticleJournal of patient-reported outcomes
Content validity and meaningful change for the FACIT-Fatigue scale in warm autoimmune hemolytic anemia: results from qualitative interview studies with patients
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Research dataAdded
-
ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania. Affiliation source
Disease researchAdded
-
Clinical trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania. Affiliation source
Clinical careAdded
-
Clinical trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Disease researchAdded
-
ArticleJCO oncology practice
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleThe AAPS journal
Best Practices and Recommendations for Non-Liquid Matrices Bioanalysis
Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Merck & Co. Affiliation source